Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – ...
Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a ...
The ArteraAI Prostate Test uses AI to analyze biopsy images, predicting hormone therapy benefits for prostate cancer patients. Approved in the US and UK, the test aids early diagnostic decisions, ...
New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men. MENLO PARK, Calif., Nov. 20, 2025 /PRNewswire/ -- MyOme, ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
BOCA RATON, Fla., Jan. 22, 2026 /PRNewswire/ -- Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular ...
But our latest research shows that prostate cancer overdiagnosis from PSA screening is mainly a risk for men over the age of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results